Entera Bio (Entera Bio) Revenue per Share : $0.00 (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Entera Bio Revenue per Share?

Entera Bio's revenue per share for the three months ended in Dec. 2023 was $0.00. Entera Bio's revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00.

During the past 12 months, the average Revenue Per Share Growth Rate of Entera Bio was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Entera Bio's Revenue per Share or its related term are showing as below:

During the past 9 years, Entera Bio's highest 3-Year average Revenue Per Share Growth Rate was -29.60% per year. The lowest was -35.90% per year. And the median was -32.75% per year.

ENTX's 3-Year Revenue Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 4.7
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

Entera Bio Revenue per Share Historical Data

The historical data trend for Entera Bio's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entera Bio Revenue per Share Chart

Entera Bio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Revenue per Share

Get a 7-Day Free Trial

0.02

0.01

Entera Bio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Revenue per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Entera Bio's Revenue per Share

For the Biotechnology subindustry, Entera Bio's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entera Bio's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entera Bio's PS Ratio distribution charts can be found below:

* The bar in red indicates where Entera Bio's PS Ratio falls into.

Entera Bio Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Entera Bio's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )	=	Revenue (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	0	/	29.008
	=	0.00

Entera Bio's Revenue Per Share for the quarter that ended in Dec. 2023 is calculated as

Revenue Per Share (Q: Dec. 2023 )	=	Revenue (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	0	/	29.595
	=	0.00

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

Entera Bio (NAS:ENTX) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Entera Bio Revenue per Share Related Terms

Thank you for viewing the detailed overview of Entera Bio's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Entera Bio (Entera Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entera Bio Ltd (NAS:ENTX) » Definitions » Revenue per Share

Comparable Companies

Traded in Other Exchanges

5DT:Germany

Address

Minrav Building - Fifth Floor, Kiryat Hadassah, Jerusalem, ISR, 9112002

Website

https://www.enterabio.com

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Executives

Haya Taitel	director	KIRYAT HADASSAH, MINRAV BUILDING, 5TH FLOOR, JERUSALEM L3 9112002
Miranda Jayne Toledano	director	C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Gerald M Lieberman	director	C/O ALLIANCE CAPITAL, 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Sean Ellis	director	KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Dana Yaacov-garbeli	officer: Israel CFO	KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Phillip Schwartz	director, officer: President of R&D	C/O ENTERA BIO LTD., KIRYAT HADASSAH, MINRAV BUILDING, 5TH FL, JERUSALEM L3 9112002
Ramesh Ratan	officer: U.S.based CFO	KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Ron Mayron	director	22A ORANIM ST, HOD HASHARON L3 4526333
Spiros Jamas	director, officer: Chief Executive Officer
Gerald M Ostrov	director	41 WATERVIEW, LONG BRANCH NJ 07740
Yonatan Malca	director	KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Roger Garceau	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Hillel Galitzer	officer: Chief Operating Officer	KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Santora Arthur C Ii	officer: Chief Medical Officer	KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002